Samuel L. Volchenboum to Young Adult
This is a "connection" page, showing publications Samuel L. Volchenboum has written about Young Adult.
Connection Strength
0.314
-
Obtaining Knowledge in Pathology Reports Through a Natural Language Processing Approach With Classification, Named-Entity Recognition, and Relation-Extraction Heuristics. JCO Clin Cancer Inform. 2019 08; 3:1-8.
Score: 0.076
-
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
Score: 0.072
-
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. J Clin Oncol. 2023 08 20; 41(24):4045-4053.
Score: 0.025
-
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589.
Score: 0.023
-
Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. JCO Clin Cancer Inform. 2021 08; 5:881-896.
Score: 0.022
-
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918.
Score: 0.020
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.016
-
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
Score: 0.016
-
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10.
Score: 0.015
-
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
Score: 0.014
-
Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
Score: 0.014